Medine.co.uk

Fasinex 5% W/V Oral Suspension

Revised: December 2015

AN. 01134/2015


SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Fasinex 5% w/v Oral Suspension


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Active substance: % w/v


Triclabendazole 5.00


Excipients:


Methyl parahydroxybenzoate 0.11

Propyl parahydroxybenzoate 0.024

Benzoic acid 0.10 as antimicrobial preservatives


For a full list of excipients, see section 6.1.


3. PHARMACEUTICAL FORM


Oral suspension.

White to cream-coloured suspension


4. CLINICAL PARTICULARS


4.1 Target species


Sheep


4.2 Indications for use, specifying the target species


For the treatment and control of liver fluke infections in sheep caused by all stages of triclabendazole susceptible Fasciola hepaticafrom 2 day old immature to adult fluke.


4.3 Contraindications


None

4.4 Special warnings for each target species


Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:


Too frequent and repeated use of anthelmintics from the same class, over an extended period of time


Underdosing which may be due to underestimation of body weight, misadministration of the product or lack of calibration of the dosing device (if any).


Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.


Resistance to triclabendazole has been reported in Fasciola species in small ruminants in a number of countries including the EU. Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of trematodes and recommendations on how to limit further selection for resistance to anthelmintics.


4.5 Special precautions for use


i. Special precautions for use in animals


Assess bodyweight as accurately as possible before calculating dose. Shake the container thoroughly before use. Clean drenching equipment before and after use. Use unaltered product from the original container.


Parasite resistance to a particular class of anthelmintic may develop following frequent repeated use or misuse of an anthelmintic of that class. To reduce this risk, dosing programmes should be discussed with your Veterinary Adviser. Efficacy of this product against liver fluke is reduced if triclabendazole-resistant strains are present. If lack of efficacy is suspected seek veterinary advice.


ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals


When using, do not eat, drink or smoke. Wash splashes from eyes and skin immediately. Take off immediately any contaminated clothing. Wash hands and exposed skin before meals and after work.


4.6 Adverse reactions (frequency and seriousness)


None.

4.7 Use during pregnancy, lactation or lay


The product can be used in pregnant ewes not producing milk for human consumption. Not authorised for use in ewes producing milk for human consumption including during the dry period.


4.8 Interaction with other medicinal products and other forms of interaction


None known.


4.9 Amounts to be administered and administration route


For oral administration. Dose: 10mg triclabendazole /kg bodyweight. (1ml Fasinex 5% per 5kg bodyweight).


Do not mix with other products. To ensure administration of a correct dose, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked.

Most types of automatic drenching guns may be used.


Do not mix with other products before administration except if premixing is done by a veterinary surgeon or a pharmacist.


Routine Flock Treatment (high risk fluke areas)

As a guide, dose all sheep exposed to fluke infested pastures preventatively at regular intervals of 10 weeks from March/April through to October/November. A dose in January may also be required. All animals grazing the pasture should be treated at these times. Any bought-in sheep should be dosed before joining the main flock. Veterinary advice should be sought with regard to specific preventative dosing regimes.


Routine Flock Treatment (moderate risk fluke areas)

Dose all sheep exposed to fluke infested pastures at regular intervals of 10 weeks throughout the fluke season, usually from September to January/February. An additional preventative treatment in the spring will assist in reducing the amount of new infestation on pasture in the following autumn.

Any bought in sheep should be treated before joining the main flock.


Treatment of acute outbreaks:The flock should be treated immediately after diagnosis is reached. Veterinary advice should be sought for subsequent dosing intervals.


4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


No treatment specified.

4.11 Withdrawal period(s)


Animals must not be slaughtered for human consumption during treatment. Sheep may be slaughtered for human consumption only after 56 days from the last treatment.

Not authorised for use in ewes producing milk for human consumption including during the dry period.

Do not use within 1 year prior to the first lambing in ewes intended to produce milk for human consumption.


5. PHARMACOLOGICAL PROPERTIES


Pharmacotherapeutic group:Antiparasitic products, insecticides and repellents; Triclabendazole


ATC vet code:QP52 AC01


5.1 Pharmacodynamic properties


Triclabendazole is a flukicide.


5.2 Pharmacokinetic particulars


Majority of oral dose in rats, sheep, goats and rabbits is eliminated in faeces after 6-10 days, as unchanged drug or products of biliary excretion. Urinary excretion is minimal. Sulphone, sulphoxide, ketone and 4-hydroxy triclabendazole derivatives are the main metabolites identified in plasma.


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


Methyl parahydroxybenzoate

Propyl parahydroxybenzoate

Benzoic acid

Povidone K30

Cellulose microcrystalline and Sodium croscarmellose (11% Sodium croscarmellose)

Disodium hydrogen phosphate dodecahydrate

Water purified


6.2 Incompatibilities


None known


6.3 Shelf life


Shelf life of veterinary medicinal product as packaged for sale: 5 years

6.4 Special precautions for storage


Protect from light. Protect from freezing. Do not store above 25°C.

Store in tightly closed original container.


6.5 Nature and composition of immediate packaging


Packs of 0.8, 2.2 or 5L in white HDPE bottles, blue polypropylene closure.

Packs of 12 or 21L in white HDPE bottles, blue HDPE closure.


Most types of drenching gun can be used.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products


Do not contaminate ponds, waterways or ditches with the product or used container. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER


Elanco Europe Ltd

Lilly House

Priestley Road

Basingstoke

Hampshire

RG24 9NL


8. MARKETING AUTHORISATION NUMBER


Vm 00879/4007


9. DATE OF FIRST AUTHORISATION


24 January 1984


10. DATE OF REVISION OF THE TEXT


December 2015


Approved: 15 December 2015


Page 5 of 5